Accumulation and photodynamic activity of chlorin e6 in cisplatin-resistant human lung cancer cells

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 3010-3017

  Horibe, Sayo ^a,b   Nagai, Junya ^a   Yumoto, Ryoko ^a   Tawa, Riichi ^b   Takano, Mikihisa ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

Author keywords

ABC transporters; Cancer chemotherapy; Cell culture; Multidrug resistance; Multidrug resistance associated proteins; P glycoprotein

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHLORIN E6; CISPLATIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER CELL CULTURE; HUMAN; HUMAN CELL; LUNG CANCER; PHOTODYNAMICS; PROTEIN EXPRESSION; TEMPERATURE SENSITIVITY;

EID: 79955588729     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22501     Document Type: Article

References (36)

1. Kelley SL, Rozencweig M. 1989. Resistance to platinum compounds: Mechanisms and beyond. Eur J Cancer Clin Oncol 25:1135-1140.
2. Stordal B, Davey M. 2007. Understanding cisplatin resistance using cellular models. IUBMB Life 59:696-699.
3. Rabik CA, Dolan ME. 2007. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9-23.
4. Nowis D, Makowski M, Stokłosa T, Legat M, Issat T, Gołab J. 2005. Direct tumor damage mechanisms of photodynamic therapy. Acta Biochim Pol 52:339-352.
5. Juzeniene A, Peng Q, Moan J. 2007. Milestones in the development of photodynamic therapy and fluorescence diagnosis. Photochem Photobiol Sci 6:1234-1245.
6. Borst P, Evers R, Kool M, Wijnholds J. 2000. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
7. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55:3-29.
8. Takano M, Yumoto R, Murakami T. 2006. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 109:137-161.
9. Murakami T, Takano M. 2008. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 4: 923-939.
10. Capella MA, Capella LS. 2003. A light in multidrug resistance: photodynamic treatment of multidrug-resistant tumors. J Biomed Sci 10:361-366.
11. Robey RW, Steadman K, Polgar O, Bates SE. 2005. ABCG2-mediated transport of photosensitizers: Potential impact on photodynamic therapy. Cancer Biol Ther 4:187-194.
12. Jendzelovský R, Mikes J, Koval' J, Soucek K, Procházková J, Kello M, Sacková V, Hofmanová J, Kozubík A, Fedorocko P. 2009. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci 8:1716-1723.
13. Patanasethanont D, Nagai J, Matsuura C, Fukui K, Sutthanut K, Sripanidkulchai BO, Yumoto R, Takano M. 2007. Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components. Eur J Pharmacol 566:67-74.
14. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72:248-254.
15. Takano M, Otani Y, Tanda M, Kawami M, Nagai J, Yumoto R. 2009. Paclitaxel-resistance conferred by altered expression of efflux and influx transporters for paclitaxel in the human hepatoma cell line, HepG2. Drug Metab Pharmacokinet 24: 418-427.
16. An R, Hagiya Y, Tamura A, Li S, Saito H, Tokushima D, Ishikawa T. 2009. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res 26:449-458.
17. Busch TM, Hahn SM. 2005. Multidrug resistance in photodynamic therapy. Cancer Biol Ther 4:195-196.
18. Korst AE, Van Der Sterre ML, Gall HE, Fichtinger-Schepman AM, Vermorken JB, Van Der Vijgh WJ. 1998. Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients. Clin Cancer Res 4:331-336.
19. Yamauchi N, Shiotani T, Yamaji Y, Fujita J, Hata Y, Irino S. 1991. Establishment and biochemical properties of cis-diamminedichloroplatinum(II)-resistant A549 lung cancer cells. Cancer Biochem Biophys 12:177-183.
20. Wu J, Hu CP, Gu QH, Li YP, Song M. 2010. Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharmacol Sin 31:93-101.
21. Liu W, Baer MR, Bowman MJ, Pera P, Zheng X, Morgan J, Pandey RA, Oseroff AR. 2007. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res 13:2463-2470.
22. Usuda J, Tsunoda Y, Ichinose S, Ishizumi T, Ohtani K, Maehara S, Ono S, Tsutsui H, Ohira T, Okunaka T, Furukawa K, Sugimoto Y, Kato H, Ikeda N. 2010. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer. Lung Cancer 67:198-204.
23. Takara K, Obata Y, Yoshikawa E, Kitada N, Sakaeda T, Ohnishi N, Yokoyama T. 2006. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer Chemother Pharmacol 58:785-793.
24. Xie SM, Fang WY, Liu TF, Yao KT, Zhong XY. 2010. Association of ABCC2 and CDDP-resistance in two sublines resistant to CDDP derived from a human nasopharyngeal carcinoma cell line. J Oncol 2010:915046.
25. Savitskiy VP, Zorin VP, Potapnev MP. 2005. Accumulation of chlorine e6 derivatives in cells with different level of expression and function activity of multidrug resistance protein P-gp 170. Exp Oncol 27:47-51.
26. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, Bates SE. 2004. Pheophorbide A is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242-1246.
27. Kobayashi T, Fujii T, Jo Y, Kinugawa K, Fujisawa M. 2004. Possible mechanism responsible for the acquisition of resistance to cis-diamminedichloroplatinum (II) by cultured human testicular seminoma cells. J Urol 171:1929-1933.
28. Nakatani K, Nakamura M, Uzawa K, Wada T, Seki N, Tanzawa H, Fujita S. 2005. Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma. Oncol Rep 13:709-714.
29. Kessel D, Whitcomb KL, Schulz V. 1992. Lipoprotein-mediated distribution of N-aspartyl chlorin-E6 in the mouse. Photochem Photobiol 56:51-56.
30. Sharma M, Dube A, Bansal H, Kumar Gupta P. 2004. Effect of pH on uptake and photodynamic action of chlorin p6 on human colon and breast adenocarcinoma cell lines. Photochem Photobiol Sci 3:231-235.
31. Mojzisova H, Bonneau S, Vever-Bizet C, Brault D. 2007. Cellular uptake and subcellular distribution of chlorin e6 as functions of pH and interactions with membranes and lipoproteins. Biochim Biophys Acta 1768:2748-2756.
32. Campbell SD, Lau WF, Xu JJ. 2009. Interaction of porphyrins with human organic anion transporting polypeptide 1B1. Chem Biol Interact 182:45-51.
33. Seki S, Kobayashi M, Itagaki S, Hirano T, Iseki K. 2009. Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. Biochim Biophys Acta 1788:911-917.
34. Dellinger M, Moreno G, Salet C, Tapiero H, Lampidis TJ. 1992. Cytotoxic and photodynamic effects of Photofrin on sensitive and multi-drug-resistant Friend leukaemia cells. Int J Radiat Biol 62:735-741.
35. Kessel D, Erickson C. 1992. Porphyrin photosensitization of multi-drug resistant cell types. Photochem Photobiol 55:397-399.
36. Teiten MH, Bezdetnaya L, Merlin JL, Bour-Dill C, Pauly ME, Dicato M, Guillemin F. 2001. Effect of meta-tetra(hydroxyphenyl)chlorin (mTHPC)-mediated photodynamic therapy on sensitive and multidrug-resistant human breast cancer cells. J Photochem Photobiol B 62:146-152.